Alnylam Pharmaceuticalsvs.Vertex Pharmaceuticals
ALNY vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 3.0× larger than Alnylam Pharmaceuticals by market cap; Vertex Pharmaceuticals trades at the lower P/E (27.9 vs 69.1); year to date, Vertex Pharmaceuticals leads (+7.1% vs −24.9%).
Side by side
| ALNY | VRTX | |
|---|---|---|
| Market cap | $39.9B | $121B |
| Price | $298.76 | $485.39 |
| Today | −4.5% | −2.2% |
| Return YTD | −24.9% | +7.1% |
| Return 1Y | −7.4% | +1.2% |
| P/E | 69.1 | 27.9 |
| P/S | 9.3 | 9.9 |
| P/B | 37.1 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where ALNY and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →